ECI-830 / Novartis - LARVOL DELTA

Phase 1/2 study of the novel CDK2 inhibitor ECI830 as a single agent and in combination with ribociclib (RIB) + fulvestrant (FUL) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and advanced solid tumors (ESMO-BC 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysis (AACR 2026) - "While CDK4/6 inhibitors such as ribociclib have transformed the treatment landscape for HR+/HER2− breast cancer, selectively targeting CDK2 has remained challenging due to the high degree of structural similarity to other essential CDK family members, such as CDK1. Moreover, ECI830 showed a favorable pharmacokinetics and tolerability profile in preclinical mouse models. Taken together, these promising preclinical data support ECI830 as a selective and potent CDK2 inhibitor for the treatment of HR+/HER2- breast cancer and other CCNE1-dysregulated advanced solid tumors, which is currently being investigated in clinical trials."

Gene Signature • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Solid Tumor • CCNE1 • CDK1 • HER-2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=280 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor